stoxline Quote Chart Rank Option Currency Glossary
  
Abiomed, Inc. (ABMD)
381.02  0 (0%)    12-21 16:00
Open: 380.78
High: 381.28
Volume: 15,702,662
  
Pre. Close: 381.02
Low: 380.545
Market Cap: 17,181(M)
Technical analysis
2023-01-27 4:42:14 PM
Short term     
Mid term     
Targets 6-month :  445.94 1-year :  520.86
Resists First :  381.79 Second :  445.94
Pivot price 380.33
Supports First :  378.24 Second :  376.04
MAs MA(5) :  380.97 MA(20) :  379.64
MA(100) :  308.19 MA(250) :  294.47
MACD MACD :  6.8 Signal :  9.2
%K %D K(14,3) :  84.4 D(3) :  84.3
RSI RSI(14): 76.2
52-week High :  381.98 Low :  219.84
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ABMD ] has closed below upper band by 33.4%. Bollinger Bands are 91.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 24 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 382.17 - 384.05 384.05 - 385.58
Low: 375.22 - 377.84 377.84 - 379.96
Close: 377.39 - 381.32 381.32 - 384.5
Company Description

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.

Headline News

Thu, 16 May 2024
Abiomed (ABMD) Reports Positive Data Backing preCARDIA System - Yahoo New Zealand News

Mon, 13 May 2024
ABIOMED (ABMD) Banks on Impella Platform, Competition Rife - Yahoo Singapore News

Sun, 12 May 2024
ABIOMED, Inc. (ABMD) Soars to 52-Week High, Time to Cash Out? - Yahoo New Zealand News

Fri, 10 May 2024
Here's Why You Should Retain Abiomed (ABMD) Stock For Now - Yahoo Singapore News

Thu, 22 Dec 2022
Johnson & Johnson completes Abiomed acquisition - Mass Device

Wed, 21 Dec 2022
A Look At Abiomed Before The $380/Share Buyout From JNJ (ABMD) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 45 (M)
Shares Float 44 (M)
Held by Insiders 2 (%)
Held by Institutions 97 (%)
Shares Short 754 (K)
Shares Short P.Month 2,080 (K)
Stock Financials
EPS 5.82
EPS Est Next Qtrly 0.56
EPS Est This Year 2.32
EPS Est Next Year 2.67
Book Value (p.s.) 34.09
Profit Margin 24.8 %
Operating Margin 22.9 %
Return on Assets (ttm) 9.5 %
Return on Equity (ttm) 18.2 %
Qtrly Rev. Growth 7.1 %
Gross Profit (p.s.) 18.7
Sales Per Share 23.73
EBITDA (p.s.) 6.08
Qtrly Earnings Growth 87 %
Operating Cash Flow 251 (M)
Levered Free Cash Flow 202 (M)
Stock Valuations
PE Ratio 65.35
PEG Ratio 5.2
Price to Book value 11.17
Price to Sales 16.05
Price to Cash Flow 68.45
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android